Autolus Therapeutics plc (AUTL)
After hours:
| Previous close | 4.8600 |
| Open | 4.9700 |
| Bid | 4.8400 x 100 |
| Ask | 4.8600 x 200 |
| Day's range | 4.8250 - 5.0500 |
| 52-week range | 1.6100 - 7.4500 |
| Volume | |
| Avg. volume | 1,550,624 |
| Market cap | 1.287B |
| Beta (5Y monthly) | 1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2000 |
| Earnings date | 01 May 2024 - 05 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.69 |
GlobeNewswireAutolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALLThe US marketing application is under review with a Prescription Drug User Fee Act (PDUFA) target action date of November 16, 2024 LONDON, April 02, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the European Medicines Agency (EMA) has accepted the Company’s Marketing
- GlobeNewswire
Autolus Therapeutics Announces Changes to its Board of Directors
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M.D., as Non-Executive Director. John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director. These changes are effective as of today, April 1, 2024. “On behalf o
